Benzinga | Oct 5, 2020 04:01PM EDT

Quanterix Reports License Deal Granting Abbott Access To Portfolio Of Bead-Based Technology Patents For Use In In Vitro Diagnostics

Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbott Laboratories (NYSE:ABT), the global healthcare company. The non-exclusive license grants Abbott access to Quanterix' portfolio of bead-based technology patents for use in in vitro diagnostic (IVD) applications.

Under the terms of the agreement, Quanterix will receive an initial license fee, milestone fees subject to the achievement by Abbott of future development, regulatory, and launch milestones and royalties on the sale of licensed products. To learn more about Quanterix, click here.